RSP vs XBI
Invesco S&P 500 Equal Weight ETF vs SPDR S&P Biotech ETF
- • RSP has the lower expense ratio at 0.20% vs 0.35% for XBI.
- • RSP pays a higher dividend yield (1.53%).
Side-by-side metrics
| Metric | RSP | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.20% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.53% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $86.40B | $8.30B |
YTD return | 7.39% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.91 | 1.09 |
P/E ratio | 22.33 | — |
Last price | $203.54 | $133.66 |
Inception | — | — |
Issuer | Invesco | State Street |
RSP top holdings
| INTC | Intel Corp | 0.38% |
| STX | Seagate Technology Holdings PLC | 0.34% |
| AMD | Advanced Micro Devices Inc | 0.33% |
| ON | ON Semiconductor Corp | 0.33% |
| SNDK | SanDisk Corp Ordinary Shares | 0.32% |
| WDC | Western Digital Corp | 0.31% |
| CIEN | Ciena Corp | 0.30% |
| MPWR | Monolithic Power Systems Inc | 0.29% |
| CNC | Centene Corp | 0.29% |
| NXPI | NXP Semiconductors NV | 0.28% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About RSP
RSP (Invesco S&P 500 Equal Weight ETF) is S&P 500 with each stock equally weighted. Managed by Invesco, the fund carries $86.4B in assets under management, an expense ratio of 0.20%, a dividend yield of 1.53%. Its largest holding is Intel Corp (INTC), which represents 0.4% of the portfolio. Real Estate is the fund's largest sector exposure at 6.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.